Kars4Kids Faces California Ad Ban Over Charity Affiliation Disclosure Financial Implications PTHS Q1 2026 Earnings Pelthos Therapeutics Surprises with NarrowerThanExpected Loss in Q1 2026 UFCS Q1 2026 Earnings Strong Underwriting Performance Drives EPS Beat LMNR Q1 2026 Earnings Loss Misses Estimates by Wide Margin as Seasonal Headwinds Persist Scholar Rock SRRK Q1 2026 Earnings ClinicalStage Biotech Reports WiderthanExpected Loss Shares Edge Lower Catalyst Pharmaceuticals Q1 2026 Earnings EPS Surpasses Estimates by 75 FRBA Q1 2026 Earnings EPS Misses Estimates by Wide Margin Despite Positive Stock Reaction